Loring Wolcott & Coolidge Fiduciary Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$487K Sell
8,457
-50
-0.6% -$2.87K ﹤0.01% 235
2026
Q1
$499K Buy
8,507
+262
+3% +$15.3K 0.01% 234
2025
Q4
$458K Sell
8,245
-20
-0.2% -$962 ﹤0.01% 250
2025
Q3
$362K Sell
8,265
-5,538
-40% -$259K ﹤0.01% 270
2025
Q2
$639K Sell
13,803
-355
-3% -$17.4K 0.01% 191
2025
Q1
$687K Hold
14,158
0.01% 181
2024
Q4
$858K Sell
14,158
-5,430
-28% -$303K 0.01% 177
2024
Q3
$1.04M Sell
19,588
-610
-3% -$28.6K 0.01% 160
2024
Q2
$832K Sell
20,198
-2,164
-10% -$96.8K 0.01% 165
2024
Q1
$1.1M Sell
22,362
-10,599
-32% -$540K 0.01% 141
2023
Q4
$1.61M Sell
32,961
-13,855
-30% -$727K 0.02% 125
2023
Q3
$2.39M Sell
46,816
-5,914
-11% -$362K 0.03% 104
2023
Q2
$3.37M Sell
52,730
-635
-1% -$42.6K 0.04% 94
2023
Q1
$3.7M Sell
53,365
-1,287
-2% -$90.8K 0.04% 95
2022
Q4
$3.93M Sell
54,652
-243
-0.4% -$18.3K 0.05% 91
2022
Q3
$3.9M Sell
54,895
-199
-0.4% -$14.4K 0.05% 87
2022
Q2
$4.24M Buy
55,094
+1,203
+2% +$91.6K 0.05% 90
2022
Q1
$3.94M Buy
53,891
+5,568
+12% +$374K 0.04% 97
2021
Q4
$3.01M Sell
48,323
-200
-0.4% -$11.7K 0.03% 107
2021
Q3
$2.87M Sell
48,523
-1,831
-4% -$121K 0.03% 103
2021
Q2
$3.37M Buy
50,354
+3,551
+8% +$232K 0.03% 101
2021
Q1
$2.96M Sell
46,803
-8,420
-15% -$524K 0.03% 103
2020
Q4
$3.43M Sell
55,223
-2,855
-5% -$176K 0.04% 100
2020
Q3
$3.5M Sell
58,078
-1,765
-3% -$106K 0.04% 93
2020
Q2
$3.52M Sell
59,843
-408
-0.7% -$24.4K 0.05% 92
2020
Q1
$3.36M Sell
60,251
-422
-0.7% -$25.8K 0.06% 86
2019
Q4
$3.9M Buy
60,673
+30,151
+99% +$1.73M 0.05% 91
2019
Q3
$1.55M Buy
30,522
+2,359
+8% +$111K 0.02% 128
2019
Q2
$1.28M Sell
28,163
-41
-0.1% -$1.91K 0.02% 139
2019
Q1
$1.35M Sell
28,204
-1,386
-5% -$69K 0.02% 138
2018
Q4
$1.54M Sell
29,590
-2,264
-7% -$122K 0.03% 125
2018
Q3
$1.98M Hold
31,854
0.03% 126
2018
Q2
$1.76M Sell
31,854
-1,946
-6% -$105K 0.03% 131
2018
Q1
$2.14M Sell
33,800
-875
-3% -$56.3K 0.04% 122
2017
Q4
$2.13M Sell
34,675
-665
-2% -$41.6K 0.04% 123
2017
Q3
$2.25M Buy
35,340
+325
+0.9% +$19K 0.04% 116
2017
Q2
$1.99M Hold
35,015
0.04% 120
2017
Q1
$1.91M Sell
35,015
-1,214
-3% -$66.6K 0.04% 119
2016
Q4
$2.12M Buy
36,229
+590
+2% +$32.3K 0.05% 113
2016
Q3
$1.92M Buy
35,639
+10,125
+40% +$650K 0.04% 118
2016
Q2
$1.88M Buy
25,514
+4,320
+20% +$305K 0.04% 118
2016
Q1
$1.35M Hold
21,194
0.03% 135
2015
Q4
$1.46M Buy
21,194
+6,121
+41% +$404K 0.04% 132
2015
Q3
$1M Hold
15,073
0.03% 155
2015
Q2
$1M Sell
15,073
-1,508
-9% -$99.4K 0.03% 155
2015
Q1
$1.07M Sell
16,581
-1,845
-10% -$116K 0.03% 152
2014
Q4
$1.09M Sell
18,426
-2,708
-13% -$153K 0.03% 149
2014
Q3
$1.08M Buy
21,134
+480
+2% +$24K 0.03% 145
2014
Q2
$1M Sell
20,654
-916
-4% -$45.1K 0.03% 149
2014
Q1
$1.12M Buy
21,570
+1,468
+7% +$78.1K 0.03% 141
2013
Q4
$1.07M Buy
20,102
+6,650
+49% +$339K 0.03% 144
2013
Q3
$623K Sell
13,452
-1,115
-8% -$48.9K 0.02% 170
2013
Q2
$651K Buy
+14,567
New +$632K 0.02% 176

Other funds holding BMY

Loring Wolcott & Coolidge Fiduciary Advisors's BMY Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors reduced its Bristol-Myers Squibb (BMY) stake by 0.59% in Q2 2026, selling an estimated $2.87K and leaving 8,457 shares worth $487K. The position accounts for ﹤0.01% of the portfolio, ranked #235.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.24M in Q2 2022. 1,603 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Loring Wolcott & Coolidge Fiduciary Advisors held 8,457 shares of Bristol-Myers Squibb worth $487K as of Q2 2026.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 50 Bristol-Myers Squibb shares in Q2 2026, an estimated $2.87K.
  • Bristol-Myers Squibb made up ﹤0.01% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #235 holding.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Bristol-Myers Squibb position peaked at $4.24M in Q2 2022.
  • 1,603 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.